CRISPR-Cas3 Platform Developer Locus Biosciences Acquires EpiBiome Phage Technology

Locus Biosciences, a developer of CRISPR-Cas3-engineered precision antibacterial products, has acquired EpiBiome’s high-throughput bacteriophage phage discovery platform for an undisclosed price, in a deal designed to help the buyer develop a leading presence in CRISPR-engineered phage therapeutics.Locus reasons that it can more rapidly develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome by combining its CRISPR-Cas3-engineered phage (crPhag